Company: ABUS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001171843-25-005076
Chunk: 0

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02. Results of Operations and Financial Condition.

On August 6, 2025, Arbutus Biopharma Corporation (the “ Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 and certain other information. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director

On August 4, 2025, Anuj Hasija notified the Company of his decision to resign from the Board of Directors of the Company (the “ Board”) and all committees thereof, effective immediately. The resignation of Mr. Hasija is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Appointment of Director

On August 4, 2025, the Board appointed Dr. Roger Sawhney to the Board, to serve until the Company’s 2026 annual general meeting of shareholders or until his successor is duly appointed and qualified, or until his earlier death, resignation or removal. Dr. Sawhney was also appointed as a member of the Board’s Audit Committee and Corporate Governance and Nominating Committee.

The Company expects to grant an initial option to acquire 157,600 common shares of the Company to Dr. Sawhney, and for the cash compensation for Dr. Sawhney to be consistent with the cash compensation generally provided to the Company’s non-employee directors. The option grant is expected to vest over a 3-year period with one-third vesting each year on the annual anniversary date of the grant, subject to Dr. Sawhney’s continued service on the Board. The option will be exercisable for 10 years from the date of the grant, at a price equal to the closing price of the Company’s common shares on the Nasdaq Stock Market on the date of the grant. The option grant will also be subject to the terms and conditions of the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “ SEC”) on May 28, 2024. Historical director compensation arrangements are described under “ Director Compensation”